Kairos Pharma said it won the 2026 Biotech Breakthrough Award for Cancer Immunology Solution of the Year for its work on ENV-105, an experimental cancer-resistance treatment. The announcement recognizes the company’s research approach; it does not change the drug’s development status or announce a new commercial or financing deal.
ENV-105, also known as carotuximab, is an investigational antibody that targets CD105, a protein Kairos says is involved in cancer drug resistance and relapse. The company is developing it alongside existing cancer treatments, with a focus on metastatic prostate cancer and non-small cell lung cancer.
Key details
- Award category: Kairos was named the winner in the Cancer Immunology Solution of the Year category of the 2026 Biotech Breakthrough Awards. The program recognizes companies, technologies and products across the life sciences sector.
- Development strategy: Kairos describes ENV-105 as a resistance-modulating treatment intended to help existing therapies remain effective longer, rather than as a standalone cancer therapy.
- Clinical update cited: The company pointed to interim results from an ongoing Phase 2 trial testing ENV-105 with apalutamide in metastatic castration-resistant prostate cancer. It said the analysis found a statistically significant difference in progression-free survival between patients receiving the combination and those receiving apalutamide alone.
- Limits of the update: The announcement did not provide the size of that difference, patient counts, or further details about the interim analysis. It also did not report a new trial milestone or a change in the study’s status.
What it means
The award is external recognition of Kairos’ approach, but it is not clinical evidence of safety or effectiveness. The investor-relevant development remains the ongoing Phase 2 trial: the company cited a positive interim comparison, but the announcement provides too little detail to assess the magnitude or context of the result.